BCTX

BriaCell Therapeutics Corp. (BCTX) | Rumor.io

BriaCell Therapeutics

BCTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,511

Bullish sentiment (50-day avg)90%

Price to earnings ratio-0.06

Market capitalization36.2M

Earnings per share-0.78

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BCTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% -0.01

Sep 17

BriaCell Therapeutics Corp. ($BCTX) cleared another major clinical hurdle, with its Phase 3 Bria-ABC study continuing without modifications after a 7th straight positive Data and Safety Monitoring Board (DSMB) review.
The company's pivotal study is being conducted under FDA Fast Track designation for metastatic breast cancer, with no safety or clinical concerns raised by the DSMB.
Analysts note that the study's primary endpoint is still at risk due to the 144th death milestone, which is unlikely to occur until December 26 to March 27, potentially affecting the study's outcome.

Generated by AI

Sentiment

Of the messages about BCTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	62.5%	62.5% -37.5	93.88% +1.97	84.66% +3.38
Bearish	37.5%	37.5% new	6.12% -1.97	15.34% -3.38

Bullish· Aug 24

BriaCell Therapeutics Corp. has announced amazing news, validating its platform and positioning it in direct competition with behemoths Merck and Moderna.
The company's recent announcement of a viable off-the-shelf melanoma treatment has sparked a buying opportunity, with the 3.44 support level (50-day MA held) and a short-term uptrend reversal, potentially leading to a 500% gain.
Despite a short attack on the news, BriaCell's stock price is seen as a good level of support, with many expecting a major news announcement soon and the potential for a significant uptrend, with the company's shorts likely to get burned.

Bearish· Jun 1

The company's recent $30 million raise is seen as a red flag, with some investors questioning the need for a second significant funding round.
The company's market capitalization may be inflated, with some investors suggesting that the low offering is a "bridge" to an expected catalyst.
The company's recent 25% drop in value is attributed to a lack of warrants in the latest raise, which is seen as a negative signal by some investors.

Generated by AI

Topics

Of the messages about BCTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.98%	76.5%
Technical Analysis	—	0%	7.02%	7.74%
Analysts	—	0%	0%	10.41%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	5.34%

Announcements· Jul 16

BriaCell Therapeutics Corp. ($BCTX) has opened its first Canadian site at Sunnybrook's Odette Cancer Centre for its pivotal Phase 3 metastatic breast cancer trial, expanding access to Bria-IMT as the study gains momentum.
The trial, which compares Bria-IMT plus a checkpoint inhibitor against physician's treatment of choice, is featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026."
Sunnybrook's Odette Cancer Centre has joined BriaCell's pivotal Phase 3 trial in metastatic breast cancer as its first Canadian site, further expanding the global reach of its Bria-IMT metastatic breast cancer study.

Technical Analysis· Jan 13

$BCTX is due for another run if strength holds, with buyers defending pullbacks and the trend still intact.
$BCTX is showing strong relative strength versus the market, holding gains while others chop, which is a bullish sign.
$BCTX needs to break the pennant and the VWAP to potentially move higher, with a pullback possibly setting up the next leg up.

Generated by AI

Community

Of the messages about BCTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	50.88%	65.65%	60.14%
Newcomers	33.33%	49.12%	34.35%	39.86%

Regulars· Sep 14

BriaCell's Phase 3 Bria-ABC study has received its 7th consecutive positive Data Safety Monitoring Board (DSMB) recommendation, with no safety concerns and no changes recommended.
The study is evaluating Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer, and the latest DSMB review supports continued progress without modifications.
BriaCell's independent DSMB has again recommended continuing the Phase 3 Bria-ABC study with no safety concerns identified, marking the 7th consecutive positive review.

Newcomers· Aug 24

Many newcomers are excited about BriaCell Therapeutics Corp. ($BCTX) and believe it will continue to rise, with some even calling it a "super stock".
There are concerns about dilution and short selling, with some users noting that the company can't dilute until September and others warning about the potential for short algos to bring the price down.
New traders are taking positions and advising others to do the same, with some even sharing their short and long strategies, including a 16% win on a trade and a plan to load on the dips and hold.

Generated by AI

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB

16d agoca.finance.yahoo.com

Stocks in play: BriaCell Therapeutics Corp.

Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.

16d agoThe Globe and Mail

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026” PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering C

22d agoYahoo Finance

BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone

BriaCell Therapeutics (NASDAQ:BCTX) shares experienced a volatile session on Monday after the biotechnology company announced that its Bria-MEL+ melanoma vaccine candidate had reached an important genetic engineering milestone. The stock initially jumped 25% following the announcement before surrendering those gains later in the session, highlighting the market’s shifting reaction to the development-stage programme.

1mo agoYahoo Finance

BriaCell stock choppy on melanoma vaccine milestone

1mo agoInvesting.com

Also Discussed

Investors talking about BCTX also mention

#	Name	Attention
1	Greenwich LifeSciences, Inc.GLSI	0%0
2	IM Cannabis Corp.IMCC	0%+0
3	Context Therapeutics Inc.CNTX	0%0
4	Alzamend Neuro, Inc.ALZN	0%0
5	Virpax Pharmaceuticals Inc.VRPX	0%0
6	Alset Inc.AEI	0%0
7	MRAI - Marpai, Inc.	——
8	Longeveron Inc. Class A Common StockLGVN	0%0
9	Innsuites Hospitality TrustIHT	0%new
10	TKAT - Takung Art Co., Ltd.	——

BriaCell Therapeutics Corp.

Healthcare
Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. BriaCell Therapeutics Corp. is best known for its cell-based oncology programs, including Bria-IMT, a lead therapy being studied for metastatic breast cancer, along with Bria-OTS, a personalized off-the-shelf immunotherapy platform, and Bria-PROS+ for prostate cancer. The company also works on BriaDx, a diagnostic tool designed to support patient selection for its immunotherapy approaches. Its current business centers on advancing cancer treatment candidates through clinical development, with an emphasis on breast cancer and other solid tumors. Based in West Vancouver, Canada, BriaCell Therapeutics Corp. operates within the immuno-oncology segment of the healthcare market, where it develops novel therapeutic and diagnostic assets aimed at improving how cancer is detected and treated.

Website

Location

Bellevue Centre

West Vancouver, BC, V7T 2X1

Canada

Social

What share of all stock conversation is about BCTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% -0.01

Sep 17

BriaCell Therapeutics Corp. ($BCTX) cleared another major clinical hurdle, with its Phase 3 Bria-ABC study continuing without modifications after a 7th straight positive Data and Safety Monitoring Board (DSMB) review.
The company's pivotal study is being conducted under FDA Fast Track designation for metastatic breast cancer, with no safety or clinical concerns raised by the DSMB.
Analysts note that the study's primary endpoint is still at risk due to the 144th death milestone, which is unlikely to occur until December 26 to March 27, potentially affecting the study's outcome.

Generated by AI

Sentiment

Of the messages about BCTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	62.5%	62.5% -37.5	93.88% +1.97	84.66% +3.38
Bearish	37.5%	37.5% new	6.12% -1.97	15.34% -3.38

Bullish· Aug 24

BriaCell Therapeutics Corp. has announced amazing news, validating its platform and positioning it in direct competition with behemoths Merck and Moderna.
The company's recent announcement of a viable off-the-shelf melanoma treatment has sparked a buying opportunity, with the 3.44 support level (50-day MA held) and a short-term uptrend reversal, potentially leading to a 500% gain.
Despite a short attack on the news, BriaCell's stock price is seen as a good level of support, with many expecting a major news announcement soon and the potential for a significant uptrend, with the company's shorts likely to get burned.

Bearish· Jun 1

The company's recent $30 million raise is seen as a red flag, with some investors questioning the need for a second significant funding round.
The company's market capitalization may be inflated, with some investors suggesting that the low offering is a "bridge" to an expected catalyst.
The company's recent 25% drop in value is attributed to a lack of warrants in the latest raise, which is seen as a negative signal by some investors.

Generated by AI

Topics

Of the messages about BCTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.98%	76.5%
Technical Analysis	—	0%	7.02%	7.74%
Analysts	—	0%	0%	10.41%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	5.34%

Announcements· Jul 16

BriaCell Therapeutics Corp. ($BCTX) has opened its first Canadian site at Sunnybrook's Odette Cancer Centre for its pivotal Phase 3 metastatic breast cancer trial, expanding access to Bria-IMT as the study gains momentum.
The trial, which compares Bria-IMT plus a checkpoint inhibitor against physician's treatment of choice, is featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026."
Sunnybrook's Odette Cancer Centre has joined BriaCell's pivotal Phase 3 trial in metastatic breast cancer as its first Canadian site, further expanding the global reach of its Bria-IMT metastatic breast cancer study.

Technical Analysis· Jan 13

$BCTX is due for another run if strength holds, with buyers defending pullbacks and the trend still intact.
$BCTX is showing strong relative strength versus the market, holding gains while others chop, which is a bullish sign.
$BCTX needs to break the pennant and the VWAP to potentially move higher, with a pullback possibly setting up the next leg up.

Generated by AI

Community

Of the messages about BCTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	50.88%	65.65%	60.14%
Newcomers	33.33%	49.12%	34.35%	39.86%

Regulars· Sep 14

BriaCell's Phase 3 Bria-ABC study has received its 7th consecutive positive Data Safety Monitoring Board (DSMB) recommendation, with no safety concerns and no changes recommended.
The study is evaluating Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer, and the latest DSMB review supports continued progress without modifications.
BriaCell's independent DSMB has again recommended continuing the Phase 3 Bria-ABC study with no safety concerns identified, marking the 7th consecutive positive review.

Newcomers· Aug 24

Many newcomers are excited about BriaCell Therapeutics Corp. ($BCTX) and believe it will continue to rise, with some even calling it a "super stock".
There are concerns about dilution and short selling, with some users noting that the company can't dilute until September and others warning about the potential for short algos to bring the price down.
New traders are taking positions and advising others to do the same, with some even sharing their short and long strategies, including a 16% win on a trade and a plan to load on the dips and hold.

Generated by AI

BriaCell Therapeutics

Social

Sep 17

Bullish· Aug 24

Bearish· Jun 1

Announcements· Jul 16

Technical Analysis· Jan 13

Regulars· Sep 14

Newcomers· Aug 24

BriaCell phase 3 breast cancer study gets seventh DSMB approval

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Stocks in play: BriaCell Therapeutics Corp.

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone

BriaCell stock choppy on melanoma vaccine milestone

Also Discussed

BriaCell Therapeutics Corp.

Company Information

Location

BriaCell phase 3 breast cancer study gets seventh DSMB approval

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Stocks in play: BriaCell Therapeutics Corp.

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone

BriaCell stock choppy on melanoma vaccine milestone

Also Discussed

Social

Sep 17

Bullish· Aug 24

Bearish· Jun 1

Announcements· Jul 16

Technical Analysis· Jan 13

Regulars· Sep 14

Newcomers· Aug 24